Immunotherapy combo shows promise in colorectal cancer fight
NCT ID NCT06154538
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding an immune checkpoint inhibitor (a type of immunotherapy) to standard chemotherapy before surgery can improve outcomes for people with locally advanced colorectal cancer. About 170 participants will be randomly assigned to receive either the combination or chemotherapy alone. The main goal is to see if the combination leads to a higher rate of complete cancer disappearance in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
immune checkpoint inhibitor (PD-1 antibody) plus FOLFOX chemotherapy
What this could lead to
If it works, this could lead to a more effective pre-surgery treatment that increases the chance of eliminating all cancer cells before surgery.
What could go wrong
This is an early phase 2 trial with only 170 participants, so results may not apply to everyone. Adding immunotherapy to chemo can also increase side effects like immune-related inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED COLORECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital/ National Cancer Center, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100038, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Qilu Hospital of Shandong University
RECRUITINGJinan, Shandong, 250000, China
Contact
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact
Contact